Michael P. Kim, MD, FACS

Peer-Reviewed Articles

1. Newhook TE, Vreeland TJ, Dewhurst WL, Wang X, Prakash L, Feng C, Bruno ML, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MHG, Tzeng CD. Clinical factors associated with practice variation in discharge opioid prescriptions after pancreatectomy. Ann Surg 272(1):163-169, 2020. e-Pub 2018. PMID: 30499795.
2. Prakash LR, Wang H, Zhao J, Nogueras-Gonzalez GM, Cloyd JM, Tzeng CD, Kim MP, Lee JE, Katz MHG. Significance of cancer cells at the vein edge in patients with pancreatic adenocarcinoma following pancreatectomy with vein resection. J Gastrointest Surg 24(2):368-379, 2020. e-Pub 2019. PMID: 30820801.
3. Cloyd JM, Prakash L, Vauthey JN, Aloia TA, Chun YS, Tzeng CW, Kim MP, Lee JE, Katz MHG. The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. Am J Surg 218(1):145-150, 2019. e-Pub 2018. PMID: 30224070.
4. Snyder RA, Prakash LR, Nogueras-Gonzalez GM, Kim MP, Aloia TA, Vauthey JN, Lee JE, Fleming JB, Katz MHG, Tzeng CD. Perioperative blood transfusions for vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. HPB (Oxford) 21(7):pii: S1365-182X(18)34525-8, 2019. e-Pub 2018. PMID: 30501986.
5. Kim BJ, Prakash L, Narula N, Davis CH, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MH, Tzeng CD. Contemporary analysis of complications associated with biliary Stents during neoadjuvant therapy for pancreatic adenocarcinoma. HPB (Oxford) 182(18):662-668, 2019. e-Pub 2018. PMID: 30522947.
6. Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, Guerrero PA, Huang Y, Zhao J, Kamyabi N, Sen S, Scheet PA, Taniguchi CM, Kim MP, Tzeng CW, Katz MH, Singhi AD, Maitra A, Alvarez HA. Single cell transcriptomics of pancreatic cancer precursors demonstrates epithelial and microenvironmental heterogeneity as an early event in neoplastic progression. Clin Cancer Res 25(7):2194-2205, 2019. e-Pub 2018. PMID: 30385653.
7. Cloyd JM, Chen HC, Wang X, Tzeng CD, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MHG. Chemotherapy versus chemoradiation as preoperatie therapy for resectable pancreatic ductal adenocarcinoma: A propensity score adjusted analysis. Pancreas 48(2):48(2):216-222, 2019. e-Pub 2019. PMID: 30629022.
8. Seth S, Li CY, Ho IL, Corti D, Loponte S, Sapio L, Del Poggetto E, Yen EY, Robinson FS, Peoples M, Karpinets T, Deem AK, Kumar T, Song X, Jiang S, Kang Y, Fleming J, Kim M, Zhang J, Maitra A, Heffernan TP, Giuliani V, Genovese G, Futreal A, Draetta GF, Carugo A, Viale A.. Pre-existing functional heterogeneity of tumorigenic compartment as the origin of chemoresistance in pancreatic tumors. CellReports 26(6):1518-1532, 2019. e-Pub 2019. PMID: 30726735.
9. Liu S, Hausmann S, Carlson SM, Fuentes ME, Francis JW, Pillai R, Lofgren SM, Hulea L, Tandoc K, Lu J, Li A, Nguyen ND, Caporicci M, Kim MP, Maitra A, Wang H, Wistuba II, Porco JA, Bassik MC, Elias JE, Song J, Topisirovic I, Van Rechem C, Mazur PK, Gozani O. METTL13 methylation of eEF1A increases translational output to promote tumorigenesis. Cell 176(3):491-504, 2019. e-Pub 2019. PMID: 30612740.
10. Koay EJ, Lee Y, Cristini V, Lowengrub JS, Kang Y, Lucas FAS, Hobbs BP, Ye R, Elganainy D, Almahariq M, Amer AM, Chatterjee D, Yan H, Park PC, Rios Perez MV, Li D, Garg N, Reiss KA, Yu S, Chauhan A, Zaid M, Nikzad N, Wolff RA, Javle M, Varadhachary GR, Shroff RT, Das P, Lee JE, Ferrari M, Maitra A, Taniguchi CM, Kim MP, Crane CH, Katz MH, Wang H, Bhosale P, Tamm EP, Fleming JB. A visually apparent and quantifiable CT imaging feature identifies biophysical subtypes of pancreatic ductal adenocarcinoma. Clin Cancer Res 24(23):5883-5894, 2018. e-Pub 2018. PMID: 30082477.
11. Li X, Lee Y, Kang Y, Dai B, Perez MR, Pratt M, Koay EJ, Kim MP, Brekken RA, Fleming JB. Hypoxia-induced autophagy of stellate cells inhibits expression and secretion of lumican into microenvironment of pancreatic ductal adenocarcinoma. Cell Death and Differ 2(26):382-393, 2018. e-Pub 2018.
12. Denbo JW, Bruno M, Dewhurst W, Kim MP, Tzeng CW, Aloia TA, Soliz J, Speer BB, Lee JE, Katz MHG. Risk-stratified clinical pathways decrease the duration of hospitalization and costs of perioperative care after pancreatectomy. Surgery 164(3):424-431, 2018. e-Pub 2018. PMID: 29807648.
13. Katz MH, Kim MP, Tzeng CW, Lee JE. Preoperative chemoradiation for borderline resectable pancreatic cancer: The new standard?. Ann Surg 268(2):223-224, 2018.
14. Ivanics T, Bergquist JR, Liu G, Kim MP, Kang Y, Katz MH, Perez MVR, Thomas RM, Fleming JB, Truty MJ. Patient-derived xenograft cryopreservation and reanimation outcomes are dependent on cryoprotectant type. Lab Invest 98(7):947-956, 2018. e-Pub 2018.
15. Snyder RA, Prakash LR, Nogueras-Gonzalez GM, Kim MP, Aloia TA, Vauthey JN, Lee JE, Fleming JB, Katz MHG, Tzeng CD. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. J Surg Oncol 117(8):1648-1654, 2018. e-Pub 2018. PMID: 29723419.
16. Cloyd JM, Nogueras-Gonzalez G, Prakash L, Petzel MQB, Parker NH, Ngo-Huang AT, Fogelman D, Denbo JW, Garg N, Kim MP, Lee JE, Tzeng CWD, Fleming JB, Katz MHG. Anthropometric changes in patients with pancreatic cancer undergoing preoperative therapy and pancreatoduodenectomy. J Gastrointest Surg 22(4):703-712, 2018. e-Pub 2017.
17. Wang YN, Lee HH, Chou CK, Yang WH, Wei Y, Chen CT, Yao J, Hsu JL, Zhu C, Ying H, Ye Y, Wang WJ, Lim SO, Xia W, Ko HW, Liu X, Liu CG, Wu X, Wang H, Li D, Prakash LR, Katz MH, Kang Y, Kim MP, Fleming JB, Fogelman D, Javle M, Maitra A, Hung MC. Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer. Cancer Cell 33(4):752-769, 2018. e-Pub 2018.
18. Fonseca AL, Kirkwood K, Kim MP, Maitra A, Koay EJ. Intraductal papillary mucinous neoplasms of the pancreas: Current understanding and future directions for stratification of malignancy risk. Pancreas 47(3):272-279, 2018.
19. Kim MP, Lozano G. Mutant p53 partners in crime. Cell Death Differ 25(1):161-168, 2018. e-Pub 2017.
20. Yamashita S, Overman MJ, Wang H, Zhao J, Okuno M, Goumard C, Tzeng CWD, Kim MP, Fleming JB, Vauthey JN, Katz MHG, Lee JE, Conrad C. Pathologic response to preoperative therapy as a novel prognosticator for ampullary and duodenal adenocarcinoma. Ann Surg Oncol 24(13):3954-3963, 2017. e-Pub 2017.
21. Cloyd JM, Wang H, Egger ME, Tzeng CD, Prakash LR, Maitra A, Varadhachary GR, Shroff R, Javle M, Fogelman D, Wolff RA, Overman MJ, Koay EJ, Das P, Herman JM, Kim MP, Vauthey JN, Aloia TA, Fleming JB, Lee JE, Katz MHG. Association of clinical factors with a major pathologic response following preoperative therapy for pancreatic ductal adenocarcinoma. JAMA Surg 152(11):1048-1056, 2017. e-Pub 2017.
22. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, Ligorio M, Chatman K, Johnston SE, Mosher CM, Brandis A, Fuks G, Gurbatri C, Gopalakrishnan V, Kim M, Hurd MW, Katz M, Fleming J, Maitra A, Smith DA, Skalak M, Bu J, Michaud M, Trauger SA, Barshack I, Golan T, Sandbank J, Flaherty KT, Mandinova A, Garrett WS, Thayer SP, Ferrone CR, Huttenhower C, Bhatia SN, Gevers D, Wargo JA, Golub TR, Straussman R. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357(6356):1156-1160, 2017. PMID: 28912244.
23. Cloyd JM, Wang H, Overman M, Zhao J, Denbo J, Prakash L, Kim MP, Shroff R, Javle M, Varadhachary GR, Fogelman D, Wolff RA, Koay EJ, Das P, Maitra A, Aloia TA, Vauthey JN, Fleming JB, Lee JE, Katz MHG. Influence of preoperative therapy on short- and long-term outcomes of patients with adenocarcinoma of the ampulla of vater. Ann Surg Oncol 24(7):2031-2039, 2017. e-Pub 2017. PMID: 28124275.
24. Vega EA, Yamashita S, Chun YS, Kim MP, Fleming JB, Katz MH, Tzeng CW, Raghav KP, Vauthey JN, Lee JE, Conrad C. Effective laparoscopic management lymph node dissection for gallbladder cancer. Ann Surg Oncol 24(7):1852, 2017. e-Pub 2017. PMID: 28168387.
25. Denbo JW, Slack RS, Bruno M, Cloyd JM, Prakash L, Fleming JB, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MHG. Selective perioperative administration of pasireotide is more cost-effective than routine administration for pancreatic fistula prophylaxis. J Gastrointest Surg 21(4):636-646, 2017. e-Pub 2017. PMID: 28050766.
26. Vega EA, Yamashita S, Shin CY, Kim MP, Fleming JB, Katz MH, Raghav KP, Vauthey JN, Lee JE, Conrad C. Laparoscopic partial splenectomy for unknown primary cancer: A stepwise approach. Ann Surg Oncol 24(4):1134, 2017. e-Pub 2016. PMID: 27942901.
27. Cloyd JM, Tran Cao HS, Petzel MQ, Denbo J, Parker NH, Liles JS, Kim MP, Lee JE, Vauthey JN, Flemin JB, Katz MHG. Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. J Surg Onc 115(2):144-150, 2017. e-Pub 2016. PMID: 27859270.
28. Prakash L, Bhosale, Priya B, Jordan MC, Kim MP, Parker N, Yao J, Dasari A, Halperin DM, Verma A, Aloia T, Lee JE, Vauthey JN, Fleming JB, Katz MHG. Role of fluorouracil, doxorubicin and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors. J Gastrointest Surg 21(1):1554-163, 2017. e-Pub 2016. PMID: 27634306.
29. Cloyd JM, Katz MHG, Prakash L, Varadhachary GR, Wolff RA, Shroff RT, Javle M, Fogelman D, Overman M, Crane CH, Koay EJ, Das P, Krishnan S, Minsky B, Lee JH, Bhutani M, Weston B, Ross W, Bhosale P, Tamm EP, Wang H, Maitra A, Kim MP, Aloia TA, Vauthey JN, Fleming JB, Abbruzzese JL, Pisters PWT, Evans DB, Lee JE. Preoperative therapy and pancreatoduodenectomy for pancreatic ductal adenocarcinoma: A 25 year single-institution experience. J Gastrointest Surg 21(1):164-174, 2017. e-Pub 2016. PMID: 27778257.
30. Denbo J, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim MP, Crane CH, Koay EJ, Krishnan S, Das P, Minsky BD, Vardhachary G, Shroff R, Wolf RA, Javle M, Overman MJ, Fogelman DF, Aloia TA, Vauthey JN, Fleming JB, Katz MHG. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. J Gastrointest Surg 20(12):1975-1985, 2016. e-Pub 2016. PMID: 27730398.
31. Conrad C, Kutlu OC, Dasari A, Chan JA, Vauthey JN, Adams DB, Kim MP, Fleming JB, Katz MHG, Lee JE. Prognostic value of lymph node status and extent of lymphadenectomy in pancreatic neuroendocrine tumors confined to and extending beyond the pancreas. J Gastrointes Surg 20(12):1966-1974, 2016. e-Pub 2016. PMID: 27714644.
32. Conrad C, Passot G, Katz MHG, Fleming JB, Kim MP, Chun YS, Aloia TA, Vauthey JN, Lee JE. Laparoscopic insulinoma enucleation from the retro-pancreatic neck: A stepwise approach. Ann Surg Oncol 23(6):2001, 2016. e-Pub 2016. PMID: 26960928.
33. Thomas RM, Truty MJ, Kim MP, Kang Y, Zhang R, Chatterjee D, Katz MHG, Fleming JB. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Ann Surg Oncol 22(6):1884-1892, 2015.
34. Kim MP, Truty MJ, Choi W, Kang Y, Chopin-Lally X, Gallick GE, Wang H, McConkey DJ, Hwang R, Logsdon C, Abbruzzesse JL, Fleming JB. Molecular profiling of direct xenograft tumors established from human pancreatic adenocarcinoma after neoadjuvant therapy. Ann Surg Oncol 19(Suppl 3):S395-403, 2012. PMID: 21701930.
35. Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS One 6(6):e20636, 2011.
36. Kim MP, Evans DB, Wang H, Abbruzzese JL, Fleming JB, Gallick GE. Generation of orthotopic and heterotopic human pancreatic cancer xenografts in immunodeficient mice. Nature Protocols 4(11):1670-1680, 2009.
37. Kopetz S, Lesslie DP, Dallas NA, Park SI, Johnson M, Parikh NU, Kim MP, Abbruzzese JL, Ellis LM, Chandra J, Gallick GE. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress. Cancer Res 69(9):3842-3849, 2009. PMID: 19383922.
38. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G 2nd, Samuel S, Kim MP, Lim SJ, Ellis LM.. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 69(5):1951-1957, 2009. PMID: 19244128.
39. Wang HQ, Kim MP, Tiano HF, Langenbach R, Smart RC. Protein kinase C-α coordinately regulates cytosolic phospholipase A2 activity and the expression of cyclooxygenase-2 through different mechanisms in mouse keratinocytes. Mol Pharmacology 59(4):860-866, 2001. PMID: 11259631.
40. Goumard C, Ogiso S, Okuno M, Fleming JB, Kim MP, Tzeng CDW, Vauthey JN, Lee JE, Conrad C. Tips and tricks of splenic vessel preservation during laparoscopic distal pancreatectomy. Surg Endosc. e-Pub 2017. PMID: 28733741.

Invited Articles

1. Kim MP, Zhang Y, Lozano G.. Mutant p53: Multiple mechanisms define biologic activity in cancer. Front Oncol 5(249), 2015.
2. Kim MP, Evans DB, Vu TM, Fleming JB. The recognition and surgical management of heritable lesions of the pancreas. Surg Oncol Clin N Am 18(1):99-119, 2009. PMID: 19056044.

Other Articles

1. Kim MP, Schroeppel TJ, Fabian TC Nonoperative management of traumatic rupture of splenosis. Injury Extra 39:147-149, 2008.

Editorials

1. Kim MP, Katz MHG. Perioperative therapy for borderline resectable pancreatic cancer: what and when?. Ann Surg Oncol 26(6):1596-1597, 2019. PMID: 30680479.
2. Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: Picking the key players. Clinical Cancer Research 14(5):1284-1285, 2008. PMID: 18316544.

Abstracts

1. Hasanov M, Mohindroo C, Rogers J, Prakash L, Overman M, Varadhachary G, Wolff R, Javle M, Fogelman D, Pant S, Katz M, Kim MP, Tzeng CW, McAllister F. The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma. ASCO Annual 2019 37(suppl; abstr e15773), 2019.
2. T. Hughes, X. Li, B. Dai, J. Deng, C. Siangco, K. Das, S. Bai, M. Hu, E. Sei, T. Seth, N. Navin, M. Kim. Wnt11 regulates migration and invasion in pancreatic ductal adenocarcinoma. AACR 2019, 2019.
3. Lingberg James, Prakash LR, Vauthey JN, Aloia TA, Tzeng CWD, Fleming JB, Lee JE, Katz MHG, Kim MP. The Impact of Tumor Differentiation on Perioperative Outcomes and Patterns of Recurrence Following Preoperative Therapy for Resectable Pancreatic Adenocarcinoma. 13th IHPBA World Congress,, 2018.
4. Simoneau E, Goumard C, Lee JE, Vauthey JN, Aloia TA, Chun YS, Conrad C, Kim MP, Katz MHG, Tzeng CWD. Improved Superior Mesenteric Artery Exposure and Reduced Blood Loss Risk Using Temporary Mesocaval Shunt for Locally Advanced Pancreatic Cancer. 13th IHPBA World Congress, 2018.
5. Newhook T, Dewhurst W, Chen HC, Wang X, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MHG, Tzeng CWD. Variation in and Predictors of Inpatient Opioid Utilization after Pancreatectomy. 13th IHPBA World Congress, 2018.
6. Dewhurst W, Newhook T, Chen HC, Wang X, Bruno M, Kim MP, Vauthey JN, Lee JE, Katz MHG, Tzeng CWD. Impact of First-day Intravenous Patient Controlled Analgesia Use on Total Inpatient Opioid Use after Pancreatectomy. 13th IHPBA World Congress, 2018.
7. Lee A, Simoneau EB, Chiang YJ, Lee J, Kim MP, Aloia T, Vauthey JN, Katz M, Tzeng CW. Is early-stage pancreatic adenocarcinoma truly early: stage migration on final pathology with surgery-first vs. neoadjuvant therapy sequencing. 13th IHPBA World Congress, 2018.
8. Snyder RA, Prakash LR, Narula N, Kim BJ, Kim MP, Aloia TA, Vauthey JN, Lee JE, Katz MHG, Tzeng CWD. Impact of perioperative blood transfusions of survival in patients with borderline resectable pancreatic adenocarcinoma after neoadjuvant therapy. Americas Hepato-Pancreato-Biliary Association Annual Meeting, 2018.
9. Conrad,C, Tzeng CWD, Lee JE, Aloia TA, Chun YS, Katz MHG, Kim MP, Vauthey JN, Simoneau E, Goumard C. Pancreaticoduodenectomy with mesocaval shunt for locally advanced pancreatic adenocarcinoma. Americas Hepato-Pancreato-Biliary Association, 2018.
10. Hughes TH, Siangco CR, Das K, Kang Y, Kim MP. WNT-11 reduces migration and invasion in pancreatic ductal adenocarcinoma. Society of Surgical Oncology (SSO) 2018 Meeting, 2018.
11. Lee A, Chiang YJ, Kim MP, Conrad C, Aloia TA, Vauthey JN, Katz MHG, Lee JE, Tzeng CWD. Validation of AJCC 8 staging system and prognostic value of lymph node ratio for resectable pancreatic adenocarcinoma after neoadjuvant therapy. The Society of Surgical Oncology (SSO) Annual Cancer Symposia, 2018.
12. Kim BJ, Vreeland T, Davis CH, Narula N, Kim MP, Katz MHG, Lee JE, Tzeng CWD, Chun YS, Conrad C, Vauthey JN, Aloia TA. Multi-institutional analysis of frequency, risk factors and outcomes for 537 simultaneous pancreatectomy/hepatectomy procedures. Langenbeck’s Archives of Surgery 19:S48, 2017. e-Pub 2017.
13. Kim MP. Mutant p53 exerts pro-metastatic functions while altering the tumor microenvironment in pancreatic adenocarcinoma. Pancreas Club Meeting, 2017.
14. Snyder RA, Prakash LR, Narula N, Kim BJ, Noguertas, GG, Katz MHG, Fleming JB, Lee JE, Aloia TA, Vauthey JN, Kim MP, Tzeng CWD. Vein resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Patency rates and outcomes associated with thrombosis. Pancreas Club meeting, 2017.
15. Snyder RA, Prakash LR, Narula N, Kim BJ, Noguertas, GG, Katz MHG, Fleming JB, Lee JE, Aloia TA, Vauthey JN, Kim MP, Tzeng CWD. Progressive decline in perioperative blood transfusions for vascular resection during pancreaticoduodenectomy for pancreatic adenocarcinoma: Identification of clinical targets for optimization. Pancreas Club Meeting, 2017.
16. Denbo JW, Bruno ML, Cloyd JM, Prakash L, Lee JE, Kim MP, Crane CH, Koay EJ, Aloia TA, Vauthey JN, Fleming JB, Katz MH. Preoperative chemoradiation for pancreatic adenocarcinoma does not increase 90-day postoperative morbidity or mortality. Society for Surgery of the Alimentary Tract Annual Meeting, 2016.
17. Cloyd JM, Crane CH, Koay EJ, Snyder RS, Das P, Krishnan S, Wang H, Kim MP, Lee JE, Varadhachary G, Javle M, Shroff R, Wolff R, Fogelman D, Katz MH. Preoperative therapy for patients with pancreatic ductal adenocarcinoma undergoing pancreatoduodenectomy: Impact of radiation dose on outcomes. Society for Surgery of the Alimentary Tract Annual Meeting, 2016.
18. Denbo JW, Slack RS, Bruno ML, Fleming JB, Kim MP, Lee JE, Katz MH. Selective administration of prophylactic pasireotide is cost effective. Society for Surgery of the Alimentary Tract Annual Meeting, 2016.
19. Conrad C, Passot G, Katz MH, Fleming JB, Kim MP, Chun YS, Aloia TA, Vauthey JN, Lee JE. Laparoscopic insulinoma enucleation from the retro-pancreatic neck: A stepwise approach. IHPBA World Congress Conference, 2016.
20. Kim MP, Tran Cao HS, Katz MH, Pisters PW, Curley SA, Vauthey JN, Aloia TA, Evans DB, Lee JE, Fleming JB. Central pancreatectomy and distal pancreatectomy for pancreatic neck lesions result in equivalent long term pancreatic function and fistula formation. Annual Meeting of the Society of Surgical Oncology, 2014.
21. Kim MP, Evans DB, Wang H, Gallick GE, Fleming JB. Prevalence of putative cancer stem cell markers in pancreatic tumor systems. American Association for Cancer Research Annual Meeting, 2009.
22. Kim MP, Evans DB, Wang H, Gallick GE, Fleming JB. Establishment of human pancreatic cancer tumor xenografts after preoperative therapy and pancreatectomy. Annual Meeting of the Society of Surgical Oncology, 2009.
23. Kim MP, Fleming JB, Evans DB, Wang HM, Gallick GE. Pancreatic cancer xenografts contain distinct populations of cells expressing the cancer stem cell marker CD133. American Society of Clinical Oncology- Gastrointestinal Cancers Symposium, 2009.
24. Kim MP, Gallick GE, Evans, DB, Wang HM, Fleming JB. Preoperative therapy limits but does not prevent engraftment of pancreatic adenocarcinoma tumor in mice after pancreatectomy. American Society of Clinical Oncology- Gastrointestinal Cancers Symposium, 2009.
25. Kim MP, Blazer DG, Abdalla EK, Pisters PW, Lee JE, Evans DB, Fleming JB. Central pancreatectomy preserves pancreatic endocrine function. Annual Pancreas Club Meeting, 2008.
26. Kim MP, Shah AN, Zhang J, Parikh N, Abbruzzese JL, Gallick GE. Gemcitabine resistance in cultured pancreatic tumor cells is associated with down regulation of PTEN and a mesenchymal phenotype. Annual American Association of Cancer Research Meeting, 2008.
27. Kim MP, Shah AN, Gallick GE. Gemcitabine resistance in cultured pancreatic tumor cells is associated with downregulation of PTEN and activation of FAK. Society of Surgical Oncology Annual Meeting, 2008.
28. Kim MP, Shah AN, Parikh NU, Gallick GE. Gemcitabine resistance in pancreatic cancer cells is associated with increased expression of stem cell-like markers and a concomitant down-regulation of PTEN and activation of AKT. American Pancreatic Association Annual Meeting, 2007.

Book Chapters

1. Kim MP and Badgwell BD. Pancreatic Neuroendocrine Tumors. In: Fischer’s Mastery of Surgery 7th Edition. Vol. 1 (45). Wolters Kluwer, 583-592, 2017.
2. eCollection. Haupt Y, Blandino G. Editorial: Human tumor-derived p53 mutants: A growing family of oncoproteins. In: Front Oncol. Wolters Kluwer Health for Mastery of Surgery, 2016.